Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies
Press Releases
Spyre Therapeutics, Inc.  
December 2, 2024

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A Antibodies

Spyre is concurrently advancing two anti-TL1A molecules into first-in-human studies

logo salamanca press

Salamanca Press

Local & Social